This is an old revision of this page, as edited by The chemistds (talk | contribs) at 22:44, 13 November 2011 (No ChemSpider ID for this record). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 22:44, 13 November 2011 by The chemistds (talk | contribs) (No ChemSpider ID for this record)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from rat) |
| Target | CD2 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| KEGG | |
| (verify) | |
Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.
References
| Immunosuppressive drugs / Immunosuppressants (L04) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (initiation) |
| ||||||||||||||
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |